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USE OF THE NATURALLY-OCCURRING 
QUINONES THYMOQUINONE AND 
DITHYMOQUINONE AS ANTINEOPLASTIC 
AND CYTOTOXIC AGENTS 
CLAIM OF PRIORITY 
This application claims priority to Provisional Applica 
tion Ser. No. 60/087,074, ?led May 28, 1998. 
FIELD OF THE INVENTION 
The present invention relates to the use of Nigella sativa 
derivatives in the treatment of carcinoma. More speci?cally, 
the invention relates to the use of the derivatives thymo 
quinone (TO) and dithymoquinone (DIM) in the treatment 
of parental and multi-drug resistant (MDR) human cancers. 
BACKGROUND OF THE INVENTION 
Various anti-cancer drugs (a.k.a., antineoplastic agents) 
are Widely used for treatment of both tumorous and leuke 
mic parental cancer cells. Certain cell lines, hoWever, are 
multi-drug resistant (MDR) and many standard anti-cancer 
drugs are MDR substrates. MDR, a phenomenon character 
iZed by over-expression of the mdr1 gene product 
P-glycoprotein and cross-resistance to multiple classes of 
anticancer drugs, including quinones, seriously complicates 
and compromises the effective chemotherapy of cancer. For 
example, as compared to their parental counterparts, many 
MDR cell lines are over 10-fold more resistant to the Well 
knoWn antineoplastic agents doxorubicin (DOX) and eto 
poside (ETP). Accordingly, there is a constant search for 
antineoplastic agents that are not MDR substrates and Which 
are therefore capable of effectively treating MDR cancers. 
Naturally occurring substances are a promising source for 
such agents. Blackseed, the seed of Nigella sativa L. 
[Ranunculaceae], has been employed for thousands of years 
as a spice and food preservative, as Well as a protective and 
curative remedy for numerous disorders. The historical 
tradition of blackseed in medicine is substantial. It is the 
blackseed referred to by the prophet Mohammed as having 
healing poWers; blackseed is also identi?ed as the curative 
black cumin in the Holy Bible, and is described as the 
Melanthion of Hippocrates and Doscorides and as the Gith 
of Pliny. Several bene?cial pharmacological effects have 
been attributed to various crude and puri?ed components of 
blackseed, including antihistaminergic, antihypertensive, 
hypoglycemic, antimicrobial, mast cell stabiliZing and anti 
in?ammatory activities. 
Blackseed preparations may have signi?cant in vitro and 
in vivo antineoplastic activity. A crude methanolic extract of 
Nigella sativa seed has an in vitro IC5O to Erlich ascites 
carcinoma, Dalton’s ascites lymphoma and sarcoma 180 
cells of 1.5, 3 and 1.5 pg/mL, respectively, While exerting 
minimal cytotoxicity to normal lymphocytes. This extract is 
also active in vivo, completely inhibiting the groWth of 
Erlich ascites carcinoma in mice. Exposure to the volatile oil 
obtained from blackseed is believed to alter the cellular 
expression of speci?c polypeptides in Jurkart T lymphoma 
cells, suggesting that changes in polypeptide expression 
might play a role in the biological activities attributed to 
blackseed. In addition to these direct anti-tumor effects, 
blackseed preparations may have potential for cancer 
chemoprevention, as Well as for reducing the toxicity of 
standard antineoplastic drugs. Topical application of a black 
seed extract can inhibit the tWo-stage initiation-promotion 
(by dimethylbenZ[a]anthracene-croton oil) of skin carcino 
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genesis in mice. Intraperitoneal injections of the same black 
seed extract may reduce the incidence of soft tissue sarco 
mas observed after 30 days of subcutaneous 
20-methylcholanthrene (MCA) injections by 67% as com 
pared to MCA-treated controls. Another chemoprotective 
effect is treatment With a crude ethanolic extract of 
blackseed, Which may signi?cantly reduce cisplatin-induced 
leukopenia and hemoglobinemia in cisplatin-treated mice. 
Although the above applications illustrate the antine 
oplastic potential of crude blackseed preparations, they do 
not establish the anti-cancer activity of speci?c blackseed 
components, in particular that of the quinones thymo 
quinone (TO) and dithymoquinone (DIM). Further, no stud 
ies have been reported Which evaluate the cytotoxicity of the 
Nigella sativa seed components TO and DIM for multi-drug 
resistant cancer cells. Thus, comprehensive cytotoxicity 
assays of these potential anticancer drugs in both parental 
and MDR tumor cell lines are useful for a thorough evalu 
ation and rational therapeutic development of these agents. 
SUMMARY OF THE INVENTION 
It is accordingly an aspect of the invention to provide 
methods and compositions for effectively treating both 
parental and multi-drug resistant cancers. 
It is another aspect of the invention to provide methods 
and compositions, as above, Which employ an extract from 
a natural source. 
It is yet another aspect of the invention to provide 
methods and compositions, as above, Which employ an 
extract from a natural source Which is inexpensive and 
readily available. 
These objects and others set forth beloW are achieved by 
treating cancer in an individual in need of such treatment by 
administering to said individual an antineoplastic amount of 
a compound selected from the group consisting of 
thymoquinone, dithimoquinone, and mixtures thereof. 
To establish antineoplastic and cytotoxic activity, a crude 
gum, ?xed oil and tWo puri?ed components of Nigella sativa 
seed, TO and DIM, Were assayed in vitro for their cytotox 
icity for several parental and multi-drug resistant (MDR) 
human tumor cell lines. Although as much as 1% W/v of the 
gum or oil Was devoid of cytotoxicity, both TO and DIM 
Were cytotoxic for all of the tested cell lines ICSO’s 78 to 393 
pM. Both the parental cell lines and their corresponding 
MDR variants, over 10-fold more resistant to the standard 
antineoplastic agents doxorubicin (DOX) and etoposide 
(ETP), as compared to their respective parental controls, 
Were equally sensitive to TO and DIM. The inclusion of the 
competitive MDR modulator quinine in the assay reversed 
MDR Dx-5 cell resistance to DOX and ETP by 6- to 16-fold, 
but had no effect on the cytotoxicity of TQ or DIM. Quinine 
also reduced MDR Dx-5 cell accumulation of the 
P-glycoprotein substrate 3H-taxol in a dose-dependent man 
ner. HoWever, neither TQ nor DIM signi?cantly altered 
cellular accumulation of 3H-taxol. The inclusion of 0.5% v/v 
of the radical scavenger DMSO in the assay reduced the 
cytotoxicity of DOX by as much as 39%, but did not affect 
that of TQ or DIM. This suggests that TO and DIM, Which 
are cytotoxic for several types of human tumor cells, may 
not be MDR substrates, and that radical generation may not 
be critical to their cytotoxic activity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a full understanding of the invention, the folloWing 
detailed description should be read in conjunction With the 
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drawing, Which is a bar graph of the effect of serial con 
centrations of QUIN, TQ and DIM in H-taxol accumulation 
assays. 
DETAILED DESCRIPTION 
It has been discovered that the quinones TQ and DIM, tWo 
important constituents of Nigella sativa seed, are cytotoxic 
for several types of human tumor cells in vitro. In contrast, 
neither the ?xed oil nor the crude gum preparation obtained 
from Nigella sativa seed exert signi?cant cytotoxic activity 
for any of the assayed tumor cell lines. Notably, both TQ and 
DIM are equally cytotoxic for both parental and MDR tumor 
cells. Their cytotoxicity Was not modulated by the presence 
of 6 pg/mL quinine, a competitive P-gp substrate that 
reverses MDR cell resistance to DOX and ETP by as much 
as 16-fold. Further, although serial concentrations of QUIN 
increase MDR Dx-5 cell uptake of the MDR substrate taxol 
in a dose-dependent manner, neither TQ nor DIM signi? 
cantly alter MDR Dx-5 cellular accumulation of taxol. These 
data suggest that these cytotoxic compounds are not 
P-glycoprotein substrates. Thus, they can function as useful 
anticancer drugs, as Well as lead compounds for novel agents 
designed to treat MDR tumors resistant to standard antine 
oplastics. 
The radical scavenger DMSO, employed both experimen 
tally and clinically to reduce the toxicity of radical gener 
ating quinones such as DOX, signi?cantly reduced the 
effective in vitro toxicity of DOX for 4 of the 5 cell lines 
tested. HoWever, the inclusion of DMSO in the cytotoxicity 
assays did not modulate the toxicity of TQ or DIM, sug 
gesting that these compounds may exert their cytotoxic 
effects through mechanisms other than radical generation. 
This characteristic might be particularly bene?cial if these 
compounds Were employed to treat those tumors resistant to 
standard agents by virtue of their expression of high levels 
of cellular antioxidants and antioxidant enZymes. 
Crude gum and expressed oil preparations from 
blackseed, as Well as the puri?ed quinones TQ and DIM 
have been evaluated in vitro for their cytotoxicity for the 
human pancreatic adenocarcinoma cell line CFPAC-1, the 
human uterine sarcoma cell line MES-SA and its MDR 
variant, Dx-5, and for the human leukemic cell line K562 
and its MDR variant, R7. Both Dx-5 and R7 cells are 
generally some 25- to 60-fold resistant to various MDR 
substrates including paclitaxel, Vinca alkaloids and to 
quinones such as doxorubicin (DOX). These cell lines Were 
chosen in order to evaluate the cytotoxicity of blackseed 
components for both solid and leukemic tumor cell lines, as 
Well as to evaluate the relative sensitivity of MDR tumor 
cells to the cytotoxic effects of TQ and DIM. In order to 
further determine Whether or not TQ and DIM are MDR 
substrates, analogous cytotoxicity experiments Were con 
ducted in the presence of quinine (QUIN), a quinoline 
alkaloid and competitive MDR substrate proven to reverse 
the MDR defect and signi?cantly increase tumor cell sen 
sitivity to MDR substrates, both in vitro and in vivo. Thus, 
the effect of QUIN on MDR tumor cell sensitivity to TQ and 
DIM might further clarify Whether or not these blackseed 
quinones are MDR substrates. An evaluation of the effect of 
QUIN, TQ and DIM on MDR Dx-5 cellular accumulation of 
the P-gp substrate 3H-taxol Was conducted in order to further 
clarify Whether or not TQ and DIM are MDR substrates. 
In addition to assaying the cytotoxicity of TQ and DIM 
for MDR tumor cells, the cytotoxicity of TQ and DIM in the 
presence of the radical scavenger dimethylsulfoxide 
(DMSO) Was also examined. Concurrent treatment With 
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DMSO reduces the in vitro cytotoxicity of radical 
generating quinones such as DOX (21). Thus, the effect, if 
any, of DMSO on the toxicity of the blackseed components 
assayed herein is thought to provide insight into the speci?c 
mechanisms responsible for their in vitro anti-cancer activ 
ity. 
The folloWing example illustrates the invention. 
EXAMPLE 
Materials. 
Blackseed (Nigella sativa seed) and the expressed oil of 
blackseed Were purchased from Al-BadaWin (Cairo, Egypt). 
Thymoquinone (TQ), ethylenediaminetetraacetic acid 
(EDTA) and methylthiaZoltetraZolium bromide (MTT) Were 
obtained from Sigma (St. Louis, Mo.). HPLC-grade metha 
nol and dimethyl sulfoxide (DMSO) Were purchased from 
Fisher Scienti?c (Spring?eld, N.J.). Doxorubicin 
(Adriamycin, DOX) Was purchased from Adria Laboratories 
(Columbus, Ohio); Etoposide (Vepesid, ETP) Was obtained 
from Bristol Myers Squibb (Princeton, N.J 
Preparation of blackseed gum and dithymoquinone. 
5 g of blackseed Were pulveriZed in a Wiley mill (20 
gauge mesh) and stirred in the dark at room temperature for 
72 hours in 500 mL methanol. The extract Was vacuum 
?ltered across Whatman No. 1 ?lter paper (Maidstone, 
England, UK) and the ?ltrate concentrated in a rotary 
evaporator in vacuo at 40° C., leaving 1.1 mL of a clear oil 
and 0.45 g of a greenish-White gum. The oil Was separated 
from the gum by exhaustive aspiration through a pipette, and 
the gum Was assayed for its cytotoxic activity as described 
beloW. 
Dithymoquinone (DIM) Was prepared by the 
UV-catalyZed dimeriZation of TQ and puri?ed by multiple 
recrystalliZations from ethanol, yielding a pale yelloW poW 
der. The identity and purity of DIM Were veri?ed using 
1H-NMR, 13C-NMR, melting point determination and 
HPLC analysis using Well knoWn techniques. 
Cell culture. 
The human pancreatic adenocarcinoma cell line CFPAC 
1, the human uterine sarcoma cell lines MES-SA (parental) 
and Dx5 (MDR) and human leukemic cell lines K562 
(parental) and R7 (MDR) Were purchased from AT CC 
(Rockville, Md.). All cell lines Were maintained in McCoy’s 
5A medium supplemented With 10% neWborn calf serum, 
100 U/mL penicillin and 100 (ug/mL streptomycin (GIBCO 
BRL, Grand Island, The cells Were cultured in 75 cm3 
tissue culture ?asks (DoW Corning, Corning, NY.) at 37° C. 
in a humidi?ed atmosphere (5% CO2/95% air) and subcul 
tured at con?uence every 3—4 days after detaching adherent 
cells With 0.4% EDTA in PBS. 
MTT cell viability assay. 
Cells Were plated in 96-well microtiter plates (DoW 
Corning, Corning, NY.) at a density of 1><104 cells/Well in 
100 pL media and incubated for 24 hours. The spent media 
Was then carefully and uniformly aspirated from each Well 
With a microtiter pipette and replaced With either 100 pL 
fresh control media or 100 ML media containing the speci?ed 
concentration of the tested compounds. Sterile stock solu 
tions of the gum, DOX or ETP dissolved in PBS and ?ltered 
through a 0.2 pM ?lter, and 0.2 M sterile-?ltered stock 
solutions of the ?xed oil, TQ or DIM dissolved in methanol 
Were diluted With normal media to prepare the serial con 
centrations of the various compounds. Control cytotoxicity 
assays revealed that the highest concentration of methanol 
used in the studies, 2% v/v, Was not toxic for any cell line. 
After exposure to serial concentrations of the speci?ed 
compounds for 72 hours, the spent control and drug 
US 6,218,434 B1 
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containing media Were aspirated and 100 ML of fresh media 
and 100 ML of a solution of 5 mg/mL MTT in PBS Were 
added to each Well. The cells Were alloWed to incubate for 
4 hours, the media aspirated, and the blue intracellular 
formaZan product dissolved in 200 ML DMSO. The UV 
absorbance of each Well Was immediately determined using 
a Dynatech MR 580 Microelisa (test Wavelength 570 
nm/reference Wavelength 634 nm). Each cytotoxicity assay 
5 
6 
effects of TQ and DIM. Notable, MDR Dx-5 cells, though 
10- to 16-fold resistant to DOX and ETP as compared to 
their MDR-negative parental cell line MES-SA, Were almost 
tWice as sensitive to DIM as Were the MES-SA cells. The 
estimated ICSO’s of the assayed compounds in each cell line 
are summariZed in the following table. 
TABLE 
Cell Line 
Drug CFPAC-l KSAZ R7 MES-SA DX-5 
Dox 8.48 1 0.26 0.64 1 0.01 9.94 1 0.4 0.89 1 0.05 8.05 1 0.41 
Dox + DMso 8.24 1 0.18 0.76 1 0.05b 12.1 1 0.5b 1.48 1 0.06b 12.5 1 0.45b 
Dox + QUIN 0.68 1 0.02 0.64 1 003° 0.72 1 0.02 0.58 1 002° 
ETP 0.39 1 0.01 15.3 1 0.40 0.33 1 0.01 4.47 1 0.26 
ETP + QUIN 0.39 1 0.02 2.95 1 0.100 0.36 1 0.01 0.56 1 0.026 
TO 206 1 8.5 275 1 15.1 235 1 10.9 188 1 9.8 255 1 9.4 
TO + DMso 234 1 12.2 250 1 13.3 232 1 9.9 156 1 8.9 232 1 13.8 
TO + QUIN 300 1 13.2 265 1 10.4 191 1 8.8 243 1 16.2 
DIM 386 1 18.5 277 1 8.9 225 1 8.5 143 1 8.7 87 1 2.8 
DIM + DMso 393 1 15.3 247 1 13.6 160 1 7.5 143 1 6.9 78 1 4.1 
DIM + QUIN 194 1 12.0 161 1 5.8 147 1 5.2 80 1 3.3 
25 
Was conducted in quadruplicate using tWo independent 
experiments. The data Were plotted as linear dose-response 
curves of percent cell viability (UV absorbance) as com 
pared to untreated controls. IC5O values are presented as the 
mean 1 SEM as determined by direct extrapolation from the 
curves. 
3H-taxol accumulation studies. 
Tritiated taxol accumulation studies Were carried out 
using MDR- MES-SA and MDR+Dx-5 cells. Brie?y, 1><106 
cells Were groWn in 2 mL media in Falcon 35x10 mm sterile 
tissue culture plates (Becton Dickinson, Lincoln Park, N.] 
After alloWing the cells to attach for 24 hours, the spent 
media Was aspirated, and 10 ML of 3H-taxol (Amersham 
Corp., Arlington Heights, Ill.) Was added to each Well 
containing either 1 mL of control media or media containing 
the speci?ed concentration of the indicated compound. After 
30 minutes incubation, the assay media Was aspirated, the 
cells Washed tWice With 1 mL of ice-cold PBS, and the cells 
lysed for 1 hour With 1 mL of 4% W/v SDS in deioniZed 
Water. The cell digest Was neutraliZed With glacial acetic 
acid, and 10 ML aliquots of the lysate Were added to 
scintillation vials containing 10 mL of Ecolite scintillation 
cocktail (1CN Biomedicals, Irvine, Calif.). Radioactivity 
Was quanti?ed using a Tri Carb C scintillation counter 
(Packard, DoWner’s Grove, Ill.). Percent accumulation ver 
sus accumulation in non-MDR MES-SA cells Was standard 
iZed per unit cellular protein present using the bichinconic 
acid method as described in Gosland, MP et al., Cancer 
Chemother Parmacol, 37:593—600, 1996, Which is hereby 
incorporated by reference. 
Results. 
The quinones TQ and DIM inhibited the groWth of 
CFPAC-1 cells in a dose-dependent manner and similarly 
inhibited the groWth of K562, R7, MES-SA and Dx-5 cells. 
In contrast, neither the ?xed oil nor the crude gum prepa 
ration demonstrated signi?cant cytotoxic activity to any of 
the tested cell lines (estimated IC5O >10% W/v oil or gum, 
data not shoWn). The MDR cell lines Dx-5 and R7 Were 
more than 10-fold resistant to the cytotoxic effects of DOX 
and ETP as compared to their respective parental controls, 
MES-SA and K562. HoWever, both the parental and MDR 
variants of these cell lines Were sensitive to the cytotoxic 
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As measured by effective ICSO, the inclusion of 6 pg/mL 
of the competitive P-gp substrate QUIN in analogous cyto 
toxicity assays reversed MDR R7 tumor cell resistance to 
DOX by 15-fold and R7 resistance to ETP by 6-fold (Table 
I). A similar effect Was observed in MDR Dx-5 cells. In the 
presence of 6 pg/mL free QUIN, Dx-5 resistance to DOX 
Was reduced by 16-fold, and resistance to ETP by 7-fold. In 
contrast, free QUIN in the assay media did not signi?cantly 
alter Dx-5 or R7 cell sensitivity to TQ or DIM. These data 
indicate that TQ and DIM are equally cytotoxic for both 
parental and MDR tumor cells, and suggest that these tWo 
quinones may not be P-gp substrates. Control cytotoxicity 
assays revealed that 6 pg/mL QUIN Was not toxic to any cell 
line tested. 
The effect of including serial concentrations of QUIN, TQ 
or DIM in the 3H-taxol accumulation assays is illustrated in 
the Figure. MDR Dx-5 cells accumulated only about 20% as 
much taxol as compared to non-MDR MES-SA parental 
cells. The presence of the competitive P-gp blocker QUIN in 
the uptake media reduced taxol accumulation signi?cantly 
and in a dose-dependent manner. HoWever, neither TQ nor 
DIM reversed the accumulation defect in Dx-5 cells. Con 
centrations of these quinones as high as 200 MM did no 
signi?cantly alter cellular accumulation of taxol. 
The inclusion of 0.2% v/v of the radical scavenger DMSO 
in culture media reduces the cytotoxicity of the quinone 
DOX to human ovarian tumor cells by as much as 39%. 
Radiolabelled uptake experiments reveal that this cytopro 
tective effect is not due to a DMSO-mediated decrease in 
cellular accumulation of DOX. In order to assess the effect 
of DMSO on the cytotoxicity of the quinones TQ and DIM, 
the previously described cytotoxicity assays Were repeated 
in media containing 0.5% v/v DMSO. Although the addition 
of 0.5% v/v DMSO did not signi?cantly alter DOX cyto 
toxicity to CFPAC-1 cells, DMSO reduced the cytotoxicity 
of DOX to K562, R7, MES-SA and Dx-5 cells by 18%, 33%, 
39%, and 22%, respectively (Table I). Interestingly, the 
cytotoxicity of TQ and DIM for the various cell lines 
examined Was not signi?cantly altered When DMSO Was 
included in the assay media. Although the cytotoxic effects 
of quinones such as TQ and DIM could be attributed to a 
number of mechanisms, including adduct formation With 
US 6,218,434 B1 
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nucleophilic residues, the failure of DMSO to modulate their 
cytotoxicity in these experiments suggests that radical for 
mation may be less important to the in vitro cytotoxicity of 
TQ and DIM than are other mechanisms. Control cytotox 
icity assays reveal that 0.5% v/v DMSO Was not cytotoxic 
for any of the tested cell lines. 
The pharmaceutical compositions of the present invention 
can also include various other components as additives or 
adjuncts. Exemplary pharmaceutically acceptable compo 
nents or adjuncts Which are employed in relevant circum 
stances include antioxidants, free radical scavenging agents, 
peptides, groWth factors antibiotics, bacteriostatic agents, 
immunosuppressives, buffering agents, anti-in?ammatory 
agents, anti-pyretics, time release binders, anaesthetics, ste 
roids and corticosteroids. Such components can provide 
additional therapeutic bene?t, act to affect the therapeutic 
action of the pharmaceutical composition, or act toWards 
preventing any potential side effects Which may be posed as 
a result of administration of the pharmaceutical composi 
tion. In certain circumstances, a compound of the present 
invention can be employed as part of a pharmaceutical 
composition With other compounds intended to prevent or 
treat a particular disorder. 
The manner in Which the compounds are administered can 
vary. The compounds can be administered by inhalation 
(e.g., in the form of an aerosol either nasally or using 
delivery articles of the type set forth in US. Pat. No. 
4,922,901 to Brooks et al.); topically (e.g., in lotion form); 
orally (e.g., in liquid form W. 
Within a solvent such as an aqueous or non-aqueous 
liquid, or Within a solid carrier; intravenously (e.g., Within a 
dextrose or saline solution); as an infusion or injection (e.g., 
as a suspension or as an emulsion in a pharmaceutically 
acceptable liquid or mixture of liquids); or transdermally 
(e.g., using a transdermal patch). Although it is possible to 
administer the compounds in the form of a bulk active 
chemical, it is preferred to present each compound in the 
form of a pharmaceutical composition or formulation for 
efficient and effective administration. Exemplary methods 
for administering such compounds Will be apparent to the 
skilled artisan. For example, the compounds can be admin 
istered in the form of a tablet, a hard gelatin capsule or as a 
time release capsule. As another example, the compounds 
can be delivered transdermally using the types of patch 
technologies available from Novartis and AlZa Corporation. 
The administration of the pharmaceutical compositions of 
the present invention can be intermittent, or at a gradual, 
continuous, constant or controlled rate to a Warm-blooded 
animal, (e.g., a mammal such as a mouse, rat, cat, rabbit, 
dog, pig, coW, or monkey); but advantageously is preferably 
administered to a human being. In addition, the time of day 
and the number of times per day that the pharmaceutical 
formulation is administered can vary. Administration pref 
erably is such that the active ingredients of the pharmaceu 
tical formulation interact With target site Within the body of 
the subject. 
In general, the invention includes the use of Nigella sativa 
components, including TQ, DIM and mixtures thereof, as 
Well as all derivatives, congeners and analogues thereof, for 
the palliation or treatment of solid and/or leukemic tumors 
in animals and/or humans When administered by any or all 
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routes of administration including, but not limited to, the 
intravenous, intramuscular, intrathecal, intraperitoneal, 
intralesional, subcutaneous, intradermal, transdermal, 
intranasal, topical, oral, buccal, rectal, vaginal, intrapulmo 
nary and inhalation routes of administration. 
The amount of TQ, DIM or mixture thereof that is used in 
treatment varies With the siZe and species of the mammal, 
the type of cancer, and the method of administration. 
Generally, the amount of active compound can vary from 
about 10—500 mg/kg body Weight per day, and preferably 
from about 10—30 mg/kg body Weight per day. The admin 
istration can be as a single dose or one or more doses 
administered over a 24-hour period. Injections are prefer 
ably in the form of dilute solutions (e.g. 10—50% v/v) and 
can be effective in the treatment of tumors and leukemias. 
For topical administration used in the treatment of skin 
cancer, a dilute solution (10—50% v/v) may be used in a 
suitable corner and applied from 1 to 3 times daily to the 
affected area for a period of from 30 days to 6 months. 
The invention also includes the use of Nigella sativa 
components, including TQ, DIM and mixtures thereof, as 
Well as all derivatives, congeners and analogues thereof, for 
the palliation and/or treatment of solid and/or leukemic 
tumors When administered orally in a suitable dosage form 
including, but not limited to, the neat compound(s), or any 
solution, elixir, syrup, tablet, capsule, suspension, emulsion, 
microemulsion or adsorption product containing said 
compound(s) and intended for their oral delivery, in the 
general dosage range of 1 to 80 mg compound(s)/kg body 
Weight, When administered in single or divided doses during 
a period of therapy of 1 to 60 days daily, every feW days, 
Weekly or monthly as deemed appropriate for therapy by a 
quali?ed practitioner of the art. 
One skilled in the art can monitor the progress of treat 
ment and adjust the length or dose of active ingredient 
accordingly. 
What is claimed is: 
1. A method for treating cancer in an individual in need of 
such treatment, comprising administering to said individual 
an antineoplastic amount of a compound selected from the 
group consisting of thymoquinone, dithymoquinone, and 
mixtures thereof and Wherein the cancer is sensitive the 
compound. 
2. The method as claimed in claim 1, Wherein said cancer 
is multi-drug resistant. 
3. The method as claimed in claim 2, Wherein the multi 
drug resistant cancer comprises a human leukemia. 
4. The method as claimed in claim 1, Wherein the cancer 
is selected from the group consisting of human pancreatic 
adenocarcinoma and human uterine sarcoma. 
5. The method according to claim 1, Wherein said cancer 
is sarcoma, carcinoma or leukemia. 
6. The method according to claim 5, Wherein said 
sarcoma, carcinoma or leukemia is multi-drug resistant. 
7. The method according to claims 5, Wherein said car 
cinoma is adenocarcinoma. 
8. The method according to claim 5, Wherein said sarcoma 
or carcinoma is pancreatic adenocarcinoma or uterine sar 
coma. 
